Back to Journals » Biologics: Targets and Therapy » Volume 10 » default

Biologics: Targets and Therapy


Archived Journals

Archive: Volume 10, 2016

Centrosome – a promising anti-cancer target

Rivera-Rivera Y, Saavedra HI

Biologics: Targets and Therapy 2016, 10:167-176

Published Date: 13 December 2016

Update on sepsis-associated acute kidney injury: emerging targeted therapies

Doyle JF, Forni LG

Biologics: Targets and Therapy 2016, 10:149-156

Published Date: 7 November 2016

Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma

Chávez-López MG, Zúñiga-García V, Pérez-Carreón JI, Avalos-Fuentes A, Escobar Y, Camacho J

Biologics: Targets and Therapy 2016, 10:139-148

Published Date: 20 September 2016

New targeted treatments for non-small-cell lung cancer – role of nivolumab

Zago G, Muller M, van den Heuvel M, Baas P

Biologics: Targets and Therapy 2016, 10:103-117

Published Date: 1 August 2016

Guanine nucleotide exchange factor H1 can be a new biomarker of melanoma

Shi J, Guo BY, Zhang Y, Hui Q, Chang P, Tao K

Biologics: Targets and Therapy 2016, 10:89-98

Published Date: 5 July 2016

Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial

Myers SP, Mulder AM, Baker DG, Robinson SR, Rolfe MI, Brooks L, Fitton JH

Biologics: Targets and Therapy 2016, 10:81-88

Published Date: 26 May 2016

Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature

van der Hilst JC, Moutschen M, Messiaen PE, Lauwerys BR, Vanderschueren S

Biologics: Targets and Therapy 2016, 10:75-80

Published Date: 4 April 2016

Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years

Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG

Biologics: Targets and Therapy 2016, 10:59-66

Published Date: 22 March 2016

Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab

Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F

Biologics: Targets and Therapy 2016, 10:53-58

Published Date: 11 March 2016

Biosimilars in the management of neutropenia: focus on filgrastim

Caselli D, Cesaro S, Aricò M

Biologics: Targets and Therapy 2016, 10:17-22

Published Date: 18 February 2016

Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients

Guariglia R, Martorelli MC, Lerose R, Telesca D, Milella MR, Musto P

Biologics: Targets and Therapy 2016, 10:1-8

Published Date: 22 January 2016